论文部分内容阅读
本文报道以血凝抑制免疫试验测定35例白血病患者血清纤维蛋白(原)降解产物(FDP)含量,观察其治疗前后变化,并对靛玉红治疗慢粒患者作了动态观察。结果表明:1)急、慢粒患者血清FDP含量于治疗后均有不同程度增加(7/11、2/11例);2)慢粒患者FDP含量与白细胞数及幼稚细胞数均呈正性相关;3)6例靛玉红治疗慢粒患者FDF含量动态观察表明,治疗后FDP含量明显下降(由32降至13.5及6.4μg/ml);白细胞数及幼稚细胞数亦然(由44.8万及41％降至13.5万及27.4％,再降至2.4万及5.6％)。此外,本组2例患者由
This article reports the determination of serum fibrinogen (FDP) content in 35 patients with leukemia by hemagglutination inhibition immunoassay to observe its changes before and after treatment, and the dynamic observation of indirubin treatment of chronic myelogenous patients. The results showed that: 1) The levels of serum FDP in acute and chronic patients increased in varying degrees after treatment (7/11 and 2/11 cases); 2) There was a positive correlation between the content of FDP and the number of leukocytes and immature cells ; 3) The dynamic observation of FDF content in 6 cases of indirubin treated chronic cor pulmonale showed that the content of FDP decreased significantly (from 32 to 13.5 and 6.4 μg / ml) after treatment; the number of white blood cells and naive cells also decreased (from 448,000 and 41% to 135,000 and 27.4% and then to 24,000 and 5.6% respectively). In addition, this group of 2 patients by